Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
<i>Background and Objective:</i> We aim to determine the efficacy and the factors associated with the effectiveness of first-line CDK4/6i (ribociclib or palbociclib) treatment in HR-positive, HER2-negative MBC patients. <i>Materials and Methods:</i> This is a retrospective, c...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/7/1279 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849246428143026176 |
|---|---|
| author | Zehra Sucuoğlu İşleyen Harun Muğlu Zeynep Alaca Topçu Mehmet Beşiroğlu Ayşe İrem Yasin Atakan Topçu Melih Şimşek Mesut Şeker Hacı Mehmet Türk |
| author_facet | Zehra Sucuoğlu İşleyen Harun Muğlu Zeynep Alaca Topçu Mehmet Beşiroğlu Ayşe İrem Yasin Atakan Topçu Melih Şimşek Mesut Şeker Hacı Mehmet Türk |
| author_sort | Zehra Sucuoğlu İşleyen |
| collection | DOAJ |
| description | <i>Background and Objective:</i> We aim to determine the efficacy and the factors associated with the effectiveness of first-line CDK4/6i (ribociclib or palbociclib) treatment in HR-positive, HER2-negative MBC patients. <i>Materials and Methods:</i> This is a retrospective, cross-sectional, and descriptive study. Ninety patients with metastatic breast cancer receiving CDK 4/6i treatment from three different oncology clinics were included in this study. <i>Results:</i> Of the patients, 56 (62.2%) received ribociclib, and 34 (37.8%) were administered palbociclib. There was no significant difference between the groups regarding age, gender, comorbidities, ECOG performance status, or menopausal status (<i>p</i> > 0.05). The cut-off values for ER, PR, and Ki-67 levels were determined via ROC curve analysis. These values were found to be 80% for ER levels, 50% for PR levels, and 30% for Ki-67 levels. PFS was significantly longer for patients with ER levels greater than 80% and Ki-67 expression levels less than 30% according to multivariate analysis. Among the patients included in our study, the median PFS was 22.41 months for the patients with Ki-67 levels of 30% and above, while the median PFS was 17.24 months for the patients with ER levels of 80% and below. Among the patients with a combined ER of 80% or less and a Ki-67 of 30% or more, the median PFS was 12.42 months (<i>p</i> < 0.001). <i>Conclusions:</i> This study demonstrates that CDK4/6i therapies led to longer PFS among patients with ER levels greater than 80% and Ki-67 expression levels less than 30%. It is essential to determine which patient group benefits more from first-line CDK4/6is therapy. |
| format | Article |
| id | doaj-art-c265e4986b2d44c1ae4fa3389c5755dc |
| institution | Kabale University |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-c265e4986b2d44c1ae4fa3389c5755dc2025-08-20T03:58:30ZengMDPI AGMedicina1010-660X1648-91442025-07-01617127910.3390/medicina61071279Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 InhibitorsZehra Sucuoğlu İşleyen0Harun Muğlu1Zeynep Alaca Topçu2Mehmet Beşiroğlu3Ayşe İrem Yasin4Atakan Topçu5Melih Şimşek6Mesut Şeker7Hacı Mehmet Türk8Department of Medical Oncology, Bezmialem Vakif University Hospital, 34093 Istanbul, TurkeyDepartment of Medical Oncology, Medipol University Hospital, 34214 Istanbul, TurkeyDepartment of Medical Oncology, Istanbul Medeniyet University Hospital, 34722 Istanbul, TurkeyDepartment of Medical Oncology, Istanbul Medeniyet University Hospital, 34722 Istanbul, TurkeyDepartment of Medical Oncology, Bezmialem Vakif University Hospital, 34093 Istanbul, TurkeyDepartment of Medical Oncology, Bezmialem Vakif University Hospital, 34093 Istanbul, TurkeyDepartment of Medical Oncology, Bezmialem Vakif University Hospital, 34093 Istanbul, TurkeyDepartment of Medical Oncology, Bezmialem Vakif University Hospital, 34093 Istanbul, TurkeyDepartment of Medical Oncology, Bezmialem Vakif University Hospital, 34093 Istanbul, Turkey<i>Background and Objective:</i> We aim to determine the efficacy and the factors associated with the effectiveness of first-line CDK4/6i (ribociclib or palbociclib) treatment in HR-positive, HER2-negative MBC patients. <i>Materials and Methods:</i> This is a retrospective, cross-sectional, and descriptive study. Ninety patients with metastatic breast cancer receiving CDK 4/6i treatment from three different oncology clinics were included in this study. <i>Results:</i> Of the patients, 56 (62.2%) received ribociclib, and 34 (37.8%) were administered palbociclib. There was no significant difference between the groups regarding age, gender, comorbidities, ECOG performance status, or menopausal status (<i>p</i> > 0.05). The cut-off values for ER, PR, and Ki-67 levels were determined via ROC curve analysis. These values were found to be 80% for ER levels, 50% for PR levels, and 30% for Ki-67 levels. PFS was significantly longer for patients with ER levels greater than 80% and Ki-67 expression levels less than 30% according to multivariate analysis. Among the patients included in our study, the median PFS was 22.41 months for the patients with Ki-67 levels of 30% and above, while the median PFS was 17.24 months for the patients with ER levels of 80% and below. Among the patients with a combined ER of 80% or less and a Ki-67 of 30% or more, the median PFS was 12.42 months (<i>p</i> < 0.001). <i>Conclusions:</i> This study demonstrates that CDK4/6i therapies led to longer PFS among patients with ER levels greater than 80% and Ki-67 expression levels less than 30%. It is essential to determine which patient group benefits more from first-line CDK4/6is therapy.https://www.mdpi.com/1648-9144/61/7/1279metastatic breast cancerCDK 4/6 inhibitorsribociclibpalbociclib |
| spellingShingle | Zehra Sucuoğlu İşleyen Harun Muğlu Zeynep Alaca Topçu Mehmet Beşiroğlu Ayşe İrem Yasin Atakan Topçu Melih Şimşek Mesut Şeker Hacı Mehmet Türk Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors Medicina metastatic breast cancer CDK 4/6 inhibitors ribociclib palbociclib |
| title | Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors |
| title_full | Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors |
| title_fullStr | Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors |
| title_full_unstemmed | Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors |
| title_short | Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors |
| title_sort | factors affecting the survival of metastatic breast cancer patients treated with cdk 4 6 inhibitors |
| topic | metastatic breast cancer CDK 4/6 inhibitors ribociclib palbociclib |
| url | https://www.mdpi.com/1648-9144/61/7/1279 |
| work_keys_str_mv | AT zehrasucuogluisleyen factorsaffectingthesurvivalofmetastaticbreastcancerpatientstreatedwithcdk46inhibitors AT harunmuglu factorsaffectingthesurvivalofmetastaticbreastcancerpatientstreatedwithcdk46inhibitors AT zeynepalacatopcu factorsaffectingthesurvivalofmetastaticbreastcancerpatientstreatedwithcdk46inhibitors AT mehmetbesiroglu factorsaffectingthesurvivalofmetastaticbreastcancerpatientstreatedwithcdk46inhibitors AT ayseiremyasin factorsaffectingthesurvivalofmetastaticbreastcancerpatientstreatedwithcdk46inhibitors AT atakantopcu factorsaffectingthesurvivalofmetastaticbreastcancerpatientstreatedwithcdk46inhibitors AT melihsimsek factorsaffectingthesurvivalofmetastaticbreastcancerpatientstreatedwithcdk46inhibitors AT mesutseker factorsaffectingthesurvivalofmetastaticbreastcancerpatientstreatedwithcdk46inhibitors AT hacımehmetturk factorsaffectingthesurvivalofmetastaticbreastcancerpatientstreatedwithcdk46inhibitors |